Gamida Cell has announced that its Phase II/III study of StemEx for the treatment of hematological malignancies such as leukemia and lymphoma met its primary endpoint of overall survival.
StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood, and is transplanted by IV administration along with the remaining, non-manipulated cells from the same unit.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study has enroled patients with hematologic malignancies following myleoablative therapy and who could not find a family related matched bone marrow donor.
The comparative study included the historical control cohort, which comprises a similar group of patients each transplanted with double cord blood during the years 2006-2010, according to the company.
The results demonstrated mortality of 15.8% in the StemEx group and 24.5% in the control group (p=0.034).
Gamida Cell president and CEO Dr Yael Margolin said, "We remain focused on completing the development of StemEx as an alternative stem/progenitor cell source for transplantation in patients who cannot find a family related matched bone marrow donor."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company said StemEx utilises a technology for expanding the therapeutic capacity of cord blood stem/progenitor cells for transplantation in adolescents and adults.
StemEx has been developed by the Gamida Cell-TEVA joint venture, which owns all global rights for the commercialisation of StemEx.
Gamida Cell said it is currently looking for a strategic partner for the global commercialisation of StemEx.
